GSK and IDEAYA partner in synthetic lethality

17th June 2020 Uncategorised 0

The deal gives GSK access to IDEAYA’s MAT2A, Pol Theta, and Werner Helicase programmes

More: GSK and IDEAYA partner in synthetic lethality
Source: News